By PETER LOFTUS
April 14, 2016 12:01 a.m. ET
The new Hepatitis C drugs are accounting for much of this increase. Will it be worth it to have brought such headline risk to the industry?
By PETER LOFTUS
April 14, 2016 12:01 a.m. ET
The new Hepatitis C drugs are accounting for much of this increase. Will it be worth it to have brought such headline risk to the industry?